Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Your new post is loading...
Your new post is loading...
Dominique Blanchard's comment,
May 13, 2015 8:46 AM
I'm going to read this paper because It will greatly impact owners of homologous recombination related patents.
|
|
In this work, the scientists used CRISPR/Cas9 editing to modify CHO cells to enforce high mTORC1 activity by knocking-out TSC2, a major mTOR inhibitory protein, or PTEN, a phosphatase that attenuates the PI3K/AKT/mTOR pathway. These data underscore manipulation of TSC as a strategy to improve performance of CHO cell in bioreactors.